DOI QR코드

DOI QR Code

Maternal Plasma Hepatocyte Growth Factor Concentrations in Women Who Subsequently Developed Preeclampsia

  • Kim, Shin Young (Laboratory of Medical Genetics, Cheil General Hospital and Women's Healthcare Center) ;
  • Park, So Yeon (Laboratory of Medical Genetics, Cheil General Hospital and Women's Healthcare Center) ;
  • Kim, Mi Jin (Laboratory of Medical Genetics, Cheil General Hospital and Women's Healthcare Center) ;
  • Kim, Moon Young (Department of Obstetrics and Gynecology, Cheil General Hospital and Women's Healthcare Center, Kwandong University College of Medicine) ;
  • Choi, Kyu Hong (Department of Obstetrics and Gynecology, Cheil General Hospital and Women's Healthcare Center, Kwandong University College of Medicine) ;
  • Kwak, Dong Wook (Department of Obstetrics and Gynecology, Cheil General Hospital and Women's Healthcare Center, Kwandong University College of Medicine) ;
  • Han, Yoo Jung (Department of Obstetrics and Gynecology, Cheil General Hospital and Women's Healthcare Center, Kwandong University College of Medicine) ;
  • Ryu, Hyun Mee (Laboratory of Medical Genetics, Cheil General Hospital and Women's Healthcare Center)
  • Received : 2012.11.20
  • Accepted : 2012.12.18
  • Published : 2012.12.31

Abstract

Purpose: The aim of this nested case-control study was to investigate the association between hepatocyte growth factor (HGF) concentrations in maternal plasma and the risk of developing preeclampsia. Materials and Methods: Plasma HGF concentration were measured in 52 women who subsequently developed preeclampsia and 104 normal pregnant women at the time of genetic amniocentesis (15-20 weeks) by enzyme-linked immunosorbent assay. Results: Maternal plasma HGF concentrations were significantly higher in women with subsequent preeclampsia (median: 737.8 ng/mL vs. 670.4 ng/mL, P=0.003) than in normal controls. However, HGF concentrations were not significantly different between subgroups by preeclamptic complications. After adjusting for potential confounding factors, women with HGF concentrations ${\geq}702.5ng/mL$ had a 3.2-fold increased risk (95% CI 2.7-5.4, P<0.001) of subsequent development of preeclampsia compared with women with HGF concentrations <702.5 ng/mL. Conclusion: Elevated maternal plasma HGF concentrations in the early second-trimester are associated with an increased risk of developing preeclampsia.

Keywords

References

  1. Sibai B, Dekker G, Kupferminc M. Pre-eclampsia. Lancet 2005;365:785-99. https://doi.org/10.1016/S0140-6736(05)71003-5
  2. Page EW. The relation between hydatid moles, relative ischemia of the gravid uterus, and the placental origin of eclampsia. Am J Obstet Gynecol 1939;37:291-3.
  3. Pijnenborg R, Anthony J, Davey DA, Rees A, Tiltman A, Vercruysse L, et al. Placental bed spiral arteries in the hypertensive disorders of pregnancy. Br J Obstet Gynaecol 1991;98:648-55. https://doi.org/10.1111/j.1471-0528.1991.tb13450.x
  4. Silasi M, Cohen B, Karumanchi SA, Rana S. Abnormal placentation, angiogenic factors, and the pathogenesis of preeclampsia. Obstet Gynecol Clin North Am 2010;37:239-53. https://doi.org/10.1016/j.ogc.2010.02.013
  5. Caniggia I, Winter J, Lye SJ, Post M. Oxygen and placental development during the first trimester: implications for the pathophysiology of preeclampsia. Placenta 2000;21 Suppl A:S25-30.
  6. Hung TH, Skepper JN, Charnock-Jones DS, Burton GJ. Hypoxiareoxygenation: a potent inducer of apoptotic changes in the human placenta and possible etiological factor in preeclampsia. Circ Res 2002;90:1274-81. https://doi.org/10.1161/01.RES.0000024411.22110.AA
  7. Soleymanlou N, Jurisica I, Nevo O, Ietta F, Zhang X, Zamudio S, et al. Molecular evidence of placental hypoxia in preeclampsia. J Clin Endocrinol Metab 2005;90:4299-308. https://doi.org/10.1210/jc.2005-0078
  8. Roberts JM, Hubel CA. Is oxidative stress the link in the two-stage model of preeclampsia? Lancet 1999;354:788-9. https://doi.org/10.1016/S0140-6736(99)80002-6
  9. Kim SY, Park SY, Kim JW, Choi JS, Ahn HK, Han JY, et al. Reduced number of endothelial progenitor colony-forming units in patients with preeclampsia. J Genet Med 2010;7:138-44. https://doi.org/10.5734/jgm.2010.7.2.138
  10. Kim SY and Ryu HM. Genetics of pre-eclampsia. J Genet Med 2011;8:17‑27. https://doi.org/10.5734/JGM.2011.8.1.17
  11. Bussolino F, Di Renzo MF, Ziche M, Bocchietto E, Olivero M, Naldini L, et al. Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth. J Cell Biol 1992;119:629-41. https://doi.org/10.1083/jcb.119.3.629
  12. Walter JJ, Sane DC. Angiostatin binds to smooth muscle cells in the coronary artery and inhibits smooth muscle cell proliferation and migration in vitro. Arterioscler Thromb Vasc Biol 1999;19:2041-8. https://doi.org/10.1161/01.ATV.19.9.2041
  13. Kauma SW, Bae-Jump V, Walsh SW. Hepatocyte growth factor stimulates trophoblast invasion: a potential mechanism for abnormal placentation in preeclampsia. J Clin Endocrinol Metab 1999;84:4092-6. https://doi.org/10.1210/jc.84.11.4092
  14. Uehara Y, Minowa O, Mori C, Shiota K, Kuno J, Noda T, et al. Placental defect and embryonic lethality in mice lacking hepatocyte growth factor/scatter factor. Nature 1995;373:702-5. https://doi.org/10.1038/373702a0
  15. ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. American College of Obstetricians and Gynecologists. Int J Gynaecol Obstet 2002;77:67-75. https://doi.org/10.1016/S0020-7292(02)80002-9
  16. Park HM. Korean Society of Obstetrics and Gynecology: Obstetrics. 4th ed. Seoul: KoonJa, 2007;626.
  17. Clark DE, Smith SK, Sharkey AM, Sowter HM, Charnock-Jones DS. Hepatocyte growth factor/scatter factor and its receptor c-met: localisation and expression in the human placenta throughout pregnancy. J Endocrinol 1996;151:459-67. https://doi.org/10.1677/joe.0.1510459
  18. Tjoa ML, Mulders MA, van Vugt JM, Blankenstein MA, Oudejans CB, van Wijk IJ. Plasma hepatocyte growth factor as a marker for small-for-gestational age fetuses. Eur J Obstet Gynecol Reprod Biol 2003;110:20-5. https://doi.org/10.1016/S0301-2115(03)00083-6
  19. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. Met, metastasis, motility and more. Nat Rev Mol Cell Biol 2003;4:915-25. https://doi.org/10.1038/nrm1261
  20. Zhang YW, Su Y, Volpert OV, Vande Woude GF. Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation. Proc Natl Acad Sci U S A 2003;100:12718-23. https://doi.org/10.1073/pnas.2135113100
  21. Ding S, Merkulova-Rainon T, Han ZC, Tobelem G. HGF receptor upregulation contributes to the angiogenic phenotype of human endothelial cells and promotes angiogenesis in vitro. Blood 2003;101:4816-22. https://doi.org/10.1182/blood-2002-06-1731
  22. Wajih N, Walter J, Sane DC. Vascular origin of a soluble truncated form of the hepatocyte growth factor receptor (c-met). Circ Res 2002;90:46-52. https://doi.org/10.1161/hh0102.102756
  23. PritchardJA, MacDonald PC. Hypertensive disorders of pregnancy. In: Pritchard JA, MacDonald PC, eds. Williams' Obstetrics. 16th ed. New York: NY Appleton-Century Crofts, 1980;665-700.
  24. Khong TY, De Wolf F, Robertson WB, Brosens I. Inadequate maternal vascular response to placentation in pregnancies complicated by pre-eclampsia and by small-for-gestational age infants. Br J Obstet Gynaecol 1986;93:1049-59. https://doi.org/10.1111/j.1471-0528.1986.tb07830.x
  25. Arkwright PD, Rademacher TW, Dwek RA, Redman CW. Pre-eclampsia is associated with an increase in trophoblast glycogen content and glycogen synthase activity, similar to that found in hydatidiform moles. J Clin Invest 1993;91:2744-53. https://doi.org/10.1172/JCI116515
  26. Redline RW, Patterson P. Pre-eclampsia is associated with an excess of proliferative immature intermediate trophoblast. Hum Pathol 1995;26:594-600. https://doi.org/10.1016/0046-8177(95)90162-0
  27. Sugawara J, Fukaya T, Murakami T, Yoshida H, Yajima A. Hepatocyte growth factor stimulated proliferation, migration, and lumen formation of human endometrial epithelial cells in vitro. Biol Reprod 1997;57:936-42. https://doi.org/10.1095/biolreprod57.4.936
  28. Wimsatt WA. New histological observations on the placenta of the sheep. Am J Anat 1950;87:391-457. https://doi.org/10.1002/aja.1000870304
  29. Iioka H. Clinical use of human hepatocyte growth factor in the early detection of HELLP syndrome. Gynecol Obstet Invest 1996;41:103-5. https://doi.org/10.1159/000292052
  30. Horibe N, Okamoto T, Itakura A, Nakanishi T, Suzuki T, Kazeto S, et al. Levels of hepatocyte growth factor in maternal serum and amniotic fluid. Am J Obstet Gynecol 1995;173:937-42. https://doi.org/10.1016/0002-9378(95)90370-4
  31. Ho RT, Liew CT, Lai KN. The expression of hepatocyte growth factor (HGF) and interleukin 6 (IL-6) in damaged human liver and kidney tissues. Hepatogastroenterology 1999;46:1904-9.
  32. Espinoza J, Romero R, Nien JK, Gomez R, Kusanovic JP, Gonçalves LF, et al. Identification of patients at risk for early onset and/or severe preeclampsia with the use of uterine artery Doppler velocimetry and placental growth factor. Am J Obstet Gynecol 2007;196:326.e1-13.
  33. Mikat B, Zeller A, Scherag A, Drommelschmidt K, Kimmig R, Schmidt M. ${\beta}$hCG and PAPP-A in first trimester: predictive factors for preeclampsia? Hypertens Pregnancy 2012;31:261-7. https://doi.org/10.3109/10641955.2011.638956
  34. Audibert F, Boucoiran I, An N, Aleksandrov N, Delvin E, Bujold E, et al. Screening for preeclampsia using first-trimester serum markers and uterine artery Doppler in nulliparous women. Am J Obstet Gynecol 2010;203:383.e1-8.
  35. Giguère Y, Charland M, Bujold E, Bernard N, Grenier S, Rousseau F, et al. Combining biochemical and ultrasonographic markers in predicting preeclampsia: a systematic review. Clin Chem 2010;56:361-75. https://doi.org/10.1373/clinchem.2009.134080